Continuous Bioprocessing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Market Overview

The continuous bioprocessing market is expected to witness a CAGR of 23% during the study period, 2022-2027.

In recent times, countries have faced a huge threat of COVID-19. As per the World Health Organization (WHO), coronavirus disease is an infectious disease, and most people infected with the COVID-19 virus will experience mild to moderate respiratory illness.

Most pharmaceutical and biotechnological companies have reallocated their resources in research and development (R&D) departments toward identifying new molecules or leads for the treatment of COVID-19.​ This has impacted the research and development activities of biopharmaceuticals for other chronic diseases.

In the early phase of the pandemic, due to the lockdown measures, trade restrictions, and high infection rate, many pharmaceutical and biotechnology companies were hit, and their work was impacted, especially R&D activities, as the clinical and other types of trials were delayed by more than six months.

According to the study “Impact of COVID19 on Operational Activities of Manufacturing Organizations—A Case Study and Industry 4.0-Based Survive-Stabilise-Sustainability (3S) Framework,” published in March 2021, restrictions imposed by local authorities have had the highest impact on operational activities, followed by unavailability of transport and unavailability of workers; scarcity of raw materials increased workload and decrease in working days have had a significant impact on the biopharmaceutical organizations. increase in machine failures, overproduction, and insufficient production to fulfill demand, also had an impact on operational activities, thus leaving a significant impact on the market.

The factors propelling the studied market growth are the growing adoption of continuous processing, increasing technological advancements in the continuous processing space, and increasing demand for biopharmaceuticals. Along with it, increasing investments and government initiatives boosting biomanufacturing will also contribute positively to market growth.

Continuous bioprocessing is being readily adopted as one of the future forms of biomanufacturing production because it operates on the same scale in both clinical production and commercialization, using flexible infrastructure that can respond quickly to changing market pressures. The use of flexible infrastructures such as single-use flow paths and small surgical vessels with the same bioreactor size will reduce significant investment while making technology transfer operations easier and maintaining quality profiles.

Additionally, the rising burden of chronic diseases such as cancer, neurological disorders, cardiovascular diseases, rare diseases, and others will propel the demand for biopharmaceuticals, thereby driving the continuous bioprocessing market. For instance, as per the 2020 statistics by GLOBOCAN 2020, an estimated number of 19,292,789 people were diagnosed with cancer in 2020. As per the same source mentioned above, the number of people suffering from cancer is estimated to reach 30.2 million by 2040. Thus, the growing burden of cancer globally will significantly increase the demand for biosimilars, thus driving the market.

Moreover, rising investments in the studied market will also lead to lucrative growth of the market. For instance, in September 2021, Gamma Biosciences made a strategic investment in Nirrin Technologies, a provider of next-generation sensors and analytics for real-time, in-process monitoring and analysis in upstream and downstream bioprocessing applications and continuous processing for the biopharma and life science industries.

• However, strict regulations for continuous bioprocessing and high equipment costs are expected to hinder market growth.

Scope of the Report

As per the scope of the report, the manufacturing of a production unit is considered continuous if it is able to process continuous flow inputs for a long period of time. The output may be continuous or split into smaller packets generated in a circular manner. The Continuous Bioprocessing market is Segmented by Product (Filtration Systems and Consumables, Chromatography Systems and Consumables, Bioreactors, Sterilizers, Centrifuges, and Others (Incubators and Shakers, Cell Culture Media, Buffers and Reagents, and Consumables)), by Application (Commercial and Research and Development), by End User (Pharmaceutical and Biotechnology Companies, CDMOs and CROs, Academic and Research Institutes), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Research and Development Segment is Expected to Account for the Largest Market Share During the Forecast Period

The research and development segment is expected to grow significantly during the study period due to the increasing research and development expenditure, rising demand for biopharmaceuticals, the establishment of new facilities, and technological advancements in the segment.

For instance, in March 2021, Transcenta announced a major breakthrough in its continuous perfusion cell culture platform by achieving volumetric productivity of > 6 g/L per day while maintaining process and product quality attributes in a state of control for a 4-week culture. This productivity improvement represents a 15-fold increase in drug substance output per year as compared to the same cell line in the conventional fed-batch process. This can increase the productivity of single-use bioreactors by approximately 130 kg or 1.3 metric tons of total drug substance per year. Thus, such advancements and increasing productivity through continuous bioprocessing will lead to lucrative growth of the market.

Furthermore, in March 2021, The United States Pharmacopeia (USP) and Phlow Corp. collaborated to build a new laboratory that will develop test methods and standards for continuous manufacturing. This establishment is focused on product development, tech transfer, and drug application filings using continuous manufacturing to foster wider adoption of continuous manufacturing by generic drugs and other pharmaceutical manufacturers.

Moreover, the establishment of continuous biomanufacturing facilities which are focused on research and development activities will also contribute to the market growth. For instance, in July 2019, GlaxoSmithKline opened a continuous manufacturing facility in Singapore with an investment of USD 95 million. Such inflow of investments will drive market growth.

• Thus, due to the above-mentioned factors, the studied segment is expected to contribute to the significant growth of the market.

To understand key trends, Download Sample Report